Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location

To assess the outcome of direct oral anticoagulants (DOACs), specifically Xa inhibitors: rivaroxaban and apixaban, for the treatment of venous thromboembolism (VTE) of atypical location (VTE-AL), portal, mesenteric, hepatic, splenic, gonadal, renal, and cerebral veins, prospectively collected data of Mayo Thrombophilia Clinic Registry were used.Patients with acute VTE-AL treated with DOACs, enrolled between March 1, 2013, and February 1, 2017,...